Mavacamten Post-marketing Surveillance in Patients With Obstructive Hypertrophic Cardiomyopathy in Japan

Sponsor
Bristol-Myers Squibb
Study ID
NCT07383025
Status
Recruiting
Apply to this trial

Conditions

  • Obstructive Hypertrophic Cardiomyopathy (oHCM)

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

The purpose of this study is to assess the real-world effectiveness and safety of mavacamten in patients with obstructive hypertrophic cardiomyopathy (HCM) receiving mavacamten in Japan

Key Dates

Start date
May 21, 2025
Status verified
Jan 2026
Primary completion
Nov 30, 2029
Completion
Nov 30, 2029

Study Design

Enrollment
200 participants (estimated)

Arms

  • Arm: Cohort 1
    Participants with obstructive hypertrophic cardiomyopathy receiving mavacamten treatment

Primary Outcome Measure

Incidence of adverse events (AEs) and/or serious AEs (SAEs) [ Time Frame: Up to 52 weeks ]

Central Contacts

  • BMS Study Connect Contact Center www.BMSStudyConnect.com
    855-907-3286
    [email protected]
  • First line of the email MUST contain NCT # and Site #.